全文获取类型
收费全文 | 141010篇 |
免费 | 10625篇 |
国内免费 | 3907篇 |
专业分类
耳鼻咽喉 | 1285篇 |
儿科学 | 2799篇 |
妇产科学 | 2646篇 |
基础医学 | 9166篇 |
口腔科学 | 3906篇 |
临床医学 | 16566篇 |
内科学 | 19866篇 |
皮肤病学 | 2419篇 |
神经病学 | 8957篇 |
特种医学 | 4544篇 |
外国民族医学 | 40篇 |
外科学 | 14027篇 |
综合类 | 20415篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5777篇 |
眼科学 | 2323篇 |
药学 | 11565篇 |
78篇 | |
中国医学 | 11540篇 |
肿瘤学 | 17598篇 |
出版年
2024年 | 206篇 |
2023年 | 2345篇 |
2022年 | 3495篇 |
2021年 | 6051篇 |
2020年 | 5643篇 |
2019年 | 5096篇 |
2018年 | 4838篇 |
2017年 | 5314篇 |
2016年 | 5650篇 |
2015年 | 5466篇 |
2014年 | 9784篇 |
2013年 | 12381篇 |
2012年 | 8148篇 |
2011年 | 8773篇 |
2010年 | 7267篇 |
2009年 | 6705篇 |
2008年 | 6541篇 |
2007年 | 6952篇 |
2006年 | 6291篇 |
2005年 | 5585篇 |
2004年 | 4583篇 |
2003年 | 4099篇 |
2002年 | 3361篇 |
2001年 | 2986篇 |
2000年 | 2517篇 |
1999年 | 2018篇 |
1998年 | 1691篇 |
1997年 | 1470篇 |
1996年 | 1268篇 |
1995年 | 1175篇 |
1994年 | 984篇 |
1993年 | 754篇 |
1992年 | 682篇 |
1991年 | 630篇 |
1990年 | 548篇 |
1989年 | 475篇 |
1988年 | 480篇 |
1987年 | 408篇 |
1986年 | 354篇 |
1985年 | 446篇 |
1984年 | 381篇 |
1983年 | 274篇 |
1982年 | 303篇 |
1981年 | 283篇 |
1980年 | 208篇 |
1979年 | 186篇 |
1978年 | 141篇 |
1977年 | 83篇 |
1976年 | 75篇 |
1975年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
21.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(6):175-183
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients. 相似文献
22.
23.
24.
25.
26.
目的:探讨胃癌患者根治术后腹腔冲洗液中CEA mRNA表达情况及其临床意义。方法: 回顾性分析了2013 年1 月至2017 年12 月在南京大学医学院附属鼓楼医院接受胃癌根治切除术后进行腹腔灌洗液CEA mRNA检测的139 名患者的病历资料,并进行术后常规随访。用RT-PCR检测139 胃癌患者根治术后腹腔灌洗液中CEA mRNA表达情况。卡方检验分析腹腔灌洗液中CEA mRNA表达与临床基本特征、组织病理学资料、血液学指标及复发方式之间的关系。采用Logistic 单因素及多因素回归分析筛查影响CEA mRNA表达水平的因素。结果:139 名患者中44 名(31.7%)患者腹腔灌洗液CEA mRNA阳性。分析显示,胃癌患者腹腔灌洗液CEA mRNA阳性表达与性别、年龄、病理分级、Lauren 分型和HER2、EGFR、VEGFR等标记物间均没有明显的关联(均P>0.05),与病理类型、脉管是否侵犯、局部浸润深度、淋巴结转移程度和临床AJCC 分期有明显的关联(均P<0.05)。CEA mRNA阳性患者腹膜复发率明显高于阴性患者(P=0.012)。Logistic 单因素回归分析显示,印戒细胞癌(P=0.04,HR=2.810,95% CI: 1.050~7.520)、T 分期(P=0.016,HR=6.329,95% CI: 1.417~28.264)、N 分期(P=0.022,HR=3.068,95% CI: 1.172~8.027)、AJCC分期(P=0.016 ,HR=3.971 ,95% CI: 1.295~12.173 )、神经侵犯(P=0.002 ,HR=6.738,95% CI: 1.995~22.757)、脉管侵犯(P<0.001,HR=16.36,95% CI: 3.85~69.512)为胃癌患者腹腔灌洗液CEA mRNA阳性表达的危险因素。Logistic 多因素回归分析显示,经过对其他因素的校正,脉管侵犯(P<0.001,HR=21.314,95% CI: 4.21~107.907)为胃癌患者腹腔灌洗液CEA mRNA阳性表达的独立危险因素。结论:胃癌腹腔灌洗CEA mRNA阳性的患者腹膜复发转移风险高且预后不良,应考虑包括腹腔局部治疗在内的更加积极的抗肿瘤治疗。 相似文献
27.
28.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
29.
30.